Two FDA-Approved Osteoporosis Drugs Go Head To Head In University Of Pittsburgh Study
PITTSBURGH, November 7, 2002 — The University of Pittsburgh Graduate School of Public Health invites local postmenopausal women to participate in a national research study that will compare two osteoporosis medications in preventing bone fractures.
Both of the drugs – raloxifene (Evista®) and alendronate (Fosamax®) – are approved by the Food and Drug Administration for the treatment of osteoporosis in older women
“Some women who have discontinued hormone replacement therapy may be looking for an alternative means of keeping their bones strong,” said Jane Cauley, Dr. P.H., associate professor of epidemiology at the University of Pittsburgh Graduate School of Public Health and principal investigator for the Pittsburgh arm of the study. “Participation in this study guarantees them a five-year course of one of two FDA-approved medications for osteoporosis, as well as the knowledge that they are helping advance this important area of clinical research.”
To be eligible for the study, called EVA, women must be between the ages of 50 and 80, not had a menstrual cycle in the past two years, plan to stay in the Pittsburgh area for the next five years and meet the study's requirements for bone density (to be determined in the clinic by the researchers). Complimentary transportation is available, and parking is provided.
Eligible women will receive, at no cost, medical tests and exams, calcium and vitamin D supplements, and one of the two study drugs for five years.
For more information about EVA or to register, please call 1-800-872-3653.